Skip to main content

Table 1 Baseline characteristics of the patients treated with or without high-dose corticosteroid before and after group adjustment

From: The relationship between high-dose corticosteroid treatment and mortality in acute respiratory distress syndrome: a retrospective and observational study using a nationwide administrative database in Japan

  Before adjustment After adjustment
High-dose corticosteroid
(n = 927)
Non-high-dose corticosteroid
(n = 1780)
p-value High-dose corticosteroid
(n = 927)
Non-high-dose corticosteroid
(n = 1780)
p-value
Sex 68.1 66.9 0.562 68.1 67.8 0.771
Age (years) 71.6 ± 0.5 67.9 ± 0.5 <  0.001 67.7 ± 1.0 69.3 ± 0.4 0.05
Hospital volume per year 10.3 ± 0.3 13.0 ± 0.3 <  0.001 12.2 ± 0.6 12.1 ± 0.2 0.806
Sepsis 12.1 22.1 <  0.001 19.9 19 0.373
Cancer 12.3 8.3 0.001 10.2 9.7 0.487
Pneumonia 52.6 62.4 <  0.001 63.6 60.3 <  0.001
Pancreatitis 0.3 1.1 0.041 0.4 0.8 0.001
Lung and abdominal trauma 0.1 0.7 0.043 0.2 0.4 0.009
Liver dysfunction 2.1 2.2 0.88 3.0 2.2 0.392
Hemodialysis 10.1 13.1 0.023 14.0 12.4 0.085
Neurological dysfunction 10.6 22.5 <  0.001 21.8 18.8 0.034
Shock 44.2 48.1 0.053 47.4 47.2 0.848
Insulin 61.7 45.9 <  0.001 48.7 51.2 0.016
Antithrombin III 9.0 15.4 <  0.001 13.9 13.2 0.537
rhTM 10.0 14.1 0.002 14.6 12.9 0.159
Heparin 58.2 61.5 0.094 62.8 61.7 0.088
Protease inhibitors 17.8 19.4 0.318 20.1 19.2 0.331
Sivelestat 72.9 56.2 <  0.001 59.7 61.8 0.074
Platelet transfusion 8.0 10.2 0.045 9.7 9.7 0.938
Red blood cell transfusion 16.4 26.5 <  0.001 24.8 23.3 0.241
Albumin administration 31.7 41.6 <  0.001 38.9 38.5 0.706
Immunoglobulin administration 18.1 23.5 0.001 22.2 21.8 0.637
Intensive-care unit 33.3 32.9 0.852 33.7 33.4 0.754
  1. Data are presented as the % or mean ± standard error, unless otherwise stated. Groups were adjusted using the inverse probability of treatment weighting method
  2. rhTM recombinant human soluble thrombomodulin